This year’s ASCO meeting promises to be an interesting one, to say the least.

In this preview we take a look at the anti-LAG-3 – it’s half a decade on from when we first wrote about this target so how is the competitive landscape doing now?  In addition, the first phase 3 trial has finally read out so there is much to discuss on this front as well.

There’s also — and this is the key part — there’s a not so obvious twist in the long tail with a look at a future pathway to success in terms of how we might continue to improve performance of IO-IO therapies.

The potential answer may well turn out to be a surprising one to many who haven’t been following the field closely…

To learn more about our pre ASCO meeting analysis to can get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by